Table 3 Distribution of patients who discontinued treatment - by LOT and time of discontinuation
LOT | Received treatment, n | Still on treatment at EOFU, n (%) | Discontinued treatment | ||
|---|---|---|---|---|---|
Time to discontinuation, months Mean (SD) | Within 6 months of LOT initiation | After 6 months of LOT initiation | |||
All patients (n = 213) | |||||
 LOT1 | 213 | 51 (23.9%) | 29.4 (31.8) | 36 (16.9%) | 126 (59.2%) |
 LOT2 | 150 | 42 (28.0%) | 20.2 (20.4) | 29 (19.3%) | 79 (52.7%) |
 LOT3 | 101 | 43 (42.6%) | 16.7 (16.2) | 20 (19.8%) | 38 (37.6%) |
 LOT4 | 48 | 18 (37.5%) | 22.2 (25.1) | 11 (22.9%) | 19 (39.6%) |
Received abatacept | |||||
 LOT1 | 68 | 51 (75.0%) | 13.0 (12.4) | 5 (7.4%) | 12 (17.6%) |
 LOT2 | 59 | 40 (67.8%) | 12.7 (10.7) | 7 (11.9%) | 12 (20.3%) |
 LOT3 | 50 | 38 (76.0%) | 12.1 (6.9) | 4 (8.0%) | 8 (16.0%) |
 LOT4 | 23 | 11 (47.8%) | 10.7 (11.0) | 5 (21.7%) | 7 (30.4%) |
Received other bDMARD | |||||
 LOT1 | 145 | 0 (0.0%) | 31.4 (32.8) | 31 (21.4%) | 114 (78.6%) |
 LOT2 | 91 | 2 (2.2%) | 21.8 (21.6) | 22 (24.2%) | 67 (73.6%) |
 LOT3 | 51 | 5 (9.8%) | 17.9 (17.7) | 16 (31.4%) | 30 (58.8%) |
 LOT4 | 25 | 7 (28.0%) | 29.9 (29.0) | 6 (24.0%) | 12 (48.0%) |